Low-Dose Aspirin Study Offers Hope for Lynch Syndrome Patients
A recent study has explored how a smaller dose of aspirin might effectively reduce cancer risks for certain patients. This finding, as noted by a prominent researcher, could shift how we view dosing for cancer prevention.
The trial included 1,879 participants diagnosed with Lynch syndrome, who were administered varying doses of aspirin. Professor Sir John Burn from Newcastle University mentioned that he plans to urge health authorities to recommend a daily dose of just 75mg for those susceptible due to this genetic condition.
Nick James, who suffers from Lynch syndrome and has tragically lost much of his family to cancer, was the first to join the trial. He expressed that the results are “massively reassuring.” Nick, a furniture maker in Newcastle, shared that he is the last surviving member of his family in the UK.
“Several relatives have faced different types of cancer, including colorectal and endometrial,” he recounted. “When we investigate our family history, patterns emerge.” He only learned about his Lynch syndrome diagnosis 13 years ago, which led him to participate in aspirin trials.
To prevent cancer, Nick enrolled in this latest study nearly a decade ago. The Cancer Prevention Project 3 study, backed by Cancer Research UK, had patients taking different daily doses: 100mg, 300mg, or even 600mg of aspirin. Interestingly, although he was on a 300mg dose during the trial, he learned about this only at its conclusion.
“Switching to a baby aspirin feels less daunting,” he shared. “I didn’t experience significant side effects, which is a plus.” The reassurance that low-dose aspirin could lower the risk of cancer for individuals with Lynch syndrome is uplifting for both him and his family.
Finding the Right Dose
Those with Lynch syndrome carry a faulty gene related to an increased likelihood of several cancers, including bowel and womb cancer. Professor Burn, who was pivotal in identifying Lynch syndrome, expressed that this group is particularly important to study due to their heightened cancer risk. “We already have guidance suggesting aspirin for Lynch syndrome patients; now, a baby aspirin should be recommended,” he stated.
Previous research led by Burn indicated a protective benefit for those taking 600mg of aspirin every day for just over two years. He added that this latest research confirms that a lower dose offers comparable protection.
He emphasized, “Statistically speaking, individuals taking a baby aspirin have a similar level of protection as those consuming higher doses, with fewer side effects.” However, it’s important to note that aspirin can cause bleeding in some patients, leading him to advocate for the minimization of dosage in those with Lynch syndrome.
The risk of developing bowel cancer, for instance, can drop from about 2% to approximately 1% a year with aspirin. Addressing the larger issue, Professor Burn highlighted the necessity of identifying individuals who remain unaware they possess Lynch syndrome. “About 150,000 individuals in the UK are estimated to have this condition, yet only a few receive testing until they face their own cancer diagnosis,” he remarked.
NHS England recognizes that with only 5-10% of patients diagnosed, increasing awareness of Lynch syndrome is crucial. When individuals do get diagnosed, there’s opportunity for essential cancer screenings and monitoring, along with the possibility of being started on a baby aspirin regimen to lower their risks.
The results of this significant study will be presented at the Cancer Prevention Research Conference in London, in collaboration with the American Cancer Society.
